Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Docosahexaenoic acid deuterated ethyl ester
- Development stage
- Preclinical
- Lead developer
- Retrotope
- Modality
- Drug Delivery Systems, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
RT011 is an orally administered, isotopically (deuterium) stabilized synthetic form of docosahexaenoic acid (DHA), developed by Retrotope. It is designed to combat oxidative stress and cellular degeneration caused by lipid peroxidation (LPO), a process implicated in the progression of degenerative diseases such as dry age-related macular degeneration (dry AMD) and geographic atrophy. By replacing natural DHA with chemically stabilized RT011 in retinal tissues, the drug aims to reduce uncontrolled LPO without disrupting the essential physiological role of DHA in visual function. Preclinical studies have shown that RT011 provides dose-dependent protection against retinal lipid peroxidation and cell damage while preserving visual function. The compound has demonstrated good safety in animal toxicity studies[1][3][4].
- Other names
- stabilized docosahexaenoic aciddeuterium-stabilized DHAD-PUFA DHA
02
Targets
Membrane phospholipid acyl chains
Beyond the preview
Go deeper on Docosahexaenoic acid deuterated ethyl ester.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Docosahexaenoic acid deuterated ethyl ester.